Thursday, April 10, 2014 7:01:24 AM
I've already shared with the board the information I learned from Nasrat after I sat down with him after the Rodman & Renshaw Conference. The conference was in August of 2013. But for more skeptical folk let me share it again. Notice that many things he mentioned have already came to fruition. He has also spoken to the immense value Elite's ART will bring to the company on several CC's including what the total market is for oxycontin. It's public knowledge and not hard to find. Should actual investors want real answers to serious questions, I urge you to call in during the next conference call and ask management to speak to them.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92946671&txt2find=30|minute
Here's What I Found Out in the 30 Minute Sit down with Dianne, Carter, Jerry and Nasrat:
~~They said the first trial should be fast tracked.....and we "should" see a product in about two years.....takes the FDA a long time for review process---around a year......so again like I've said 1--3 years before the REAL $$$$$$
~~Conservatively with a 20% cut of the $2.5 Billion Oxycontin Market......Nasrat did the math in front of me using a P/E ration of 10......with one ART product Elite could hit $5 a share with current shares out there!! BUT THen......he said what does that get you if Elite puts out 3 or 4 ART products!!
~~Nasrat purchased every single share of Elite out of his own pocket......9 million in his person JP Morgan account and 2 million in his retirement account.....and he is the only one that cashed out his previous warrants if I remember correctly!
~~One Major CEO of a Pharma company expressed interest......Nasrat said he was interested in sharing rights to the first Oxy/Nal product.....the CEO said he wants the whole thing.....Nasrat said only at fair market value....not .08!!! Nasrat is very sharp in person.
~~Elite doesn't need all 13 Anda's.......only 3 or 4 to become CFP......then Elite can sell the rest for additional profit if it wants....Elite doesn't have the space for all those Anda's....and when Elite starts putting out ART products Nasrat said they will stop with some of the Andas they are already producing....so they have more space for ART products! ....and can sell those ANDAS for more $$$$$$ down the road. Very smart!!!!
~~Nasrat said that by the looks of the studies already done that Elite should have no problem marketing their first ART product.....then he said that is IMO only.....but reiterated why he bought 11 Million shares on the open market!!!
~~First trial starts without any unforeseen problems in about 2 months!!.....and take around 6 months give or take......
~~Plenty of potential partners have been calling Elite especially in the last 4-5 weeks....Nasrat said he is not worried about a good solid partner!!! He gets to choose amongst a few.....and for a better than 50/50 split is what he said!!!
~~Carter said the market is bound to wake up in the next six months and that he is rather surprised it hasn't already done so.....and Aldwyn Carter liked your DD btw
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92946671&txt2find=30|minute
Here's What I Found Out in the 30 Minute Sit down with Dianne, Carter, Jerry and Nasrat:
~~They said the first trial should be fast tracked.....and we "should" see a product in about two years.....takes the FDA a long time for review process---around a year......so again like I've said 1--3 years before the REAL $$$$$$
~~Conservatively with a 20% cut of the $2.5 Billion Oxycontin Market......Nasrat did the math in front of me using a P/E ration of 10......with one ART product Elite could hit $5 a share with current shares out there!! BUT THen......he said what does that get you if Elite puts out 3 or 4 ART products!!
~~Nasrat purchased every single share of Elite out of his own pocket......9 million in his person JP Morgan account and 2 million in his retirement account.....and he is the only one that cashed out his previous warrants if I remember correctly!
~~One Major CEO of a Pharma company expressed interest......Nasrat said he was interested in sharing rights to the first Oxy/Nal product.....the CEO said he wants the whole thing.....Nasrat said only at fair market value....not .08!!! Nasrat is very sharp in person.
~~Elite doesn't need all 13 Anda's.......only 3 or 4 to become CFP......then Elite can sell the rest for additional profit if it wants....Elite doesn't have the space for all those Anda's....and when Elite starts putting out ART products Nasrat said they will stop with some of the Andas they are already producing....so they have more space for ART products! ....and can sell those ANDAS for more $$$$$$ down the road. Very smart!!!!
~~Nasrat said that by the looks of the studies already done that Elite should have no problem marketing their first ART product.....then he said that is IMO only.....but reiterated why he bought 11 Million shares on the open market!!!
~~First trial starts without any unforeseen problems in about 2 months!!.....and take around 6 months give or take......
~~Plenty of potential partners have been calling Elite especially in the last 4-5 weeks....Nasrat said he is not worried about a good solid partner!!! He gets to choose amongst a few.....and for a better than 50/50 split is what he said!!!
~~Carter said the market is bound to wake up in the next six months and that he is rather surprised it hasn't already done so.....and Aldwyn Carter liked your DD btw
Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
